Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.

MLA

Anurathapan, Usanarat, et al. “Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk Stratification.” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 20, no. 12, Dec. 2014, pp. 2066–71. EBSCOhost, https://doi.org/10.1016/j.bbmt.2014.07.016.

APA

Anurathapan, U., Pakakasama, S., Mekjaruskul, P., Sirachainan, N., Songdej, D., Chuansumrit, A., Charoenkwan, P., Jetsrisuparb, A., Sanpakit, K., Pongtanakul, B., Rujkijyanont, P., Meekaewkunchorn, A., Sruamsiri, R., Ungkanont, A., Issaragrisil, S., Andersson, B. S., & Hongeng, S. (2014). Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 20(12), 2066–2071. https://doi.org/10.1016/j.bbmt.2014.07.016

Chicago

Anurathapan, Usanarat, Samart Pakakasama, Pimsiri Mekjaruskul, Nongnuch Sirachainan, Duantida Songdej, Ampaiwan Chuansumrit, Pimlak Charoenkwan, et al. 2014. “Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk Stratification.” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 20 (12): 2066–71. doi:10.1016/j.bbmt.2014.07.016.